Persons who purchased or paid for (in whole or in part) Paxil CR(R) and insurance companies and other entities that reimbursed for (in whole or in part) Paxil CR(R) in the United States and its territories may be eligible for relief as part of a $28 million Proposed Settlement. The lawsuit claims that the Paxil CR(R) tablets GlaxoSmithKline ("GSK") manufactured between April 1, 2002 and March 4, 2005 contained a manufacturing defect that caused some of the tablets to split apart. GSK denies all of these claims and any liability.

If approved, the Proposed Settlement will provide up to $28 million to settle the claims in the lawsuit. Some of this money will be paid to insurance companies and other entities that made reimbursements for (in whole or in part) Paxil CR(R) and some of this money will be paid to consumers who purchased or paid for (in whole or in part) Paxil CR(R). The recovery available to insurance companies and other Third-Party Payors ("TPPs") will be based on their number of covered lives as of December 31, 2004. Consumer class members' recovery will be based on the number of Paxil CR(R) tablets that they paid for or purchased, up to $150, that were defective in that they were split before they were removed from the container in which they were purchased.

Potential Class Members do not need to do anything to stay in the class. However, they must submit a Claim Form if they wish to obtain money from the Proposed Settlement. Claim Forms are available by visiting the website www.SimonetPaxilCRSettlement.com or by calling 1-866-458-3186. Claim Forms must be postmarked by August 10, 2009.

Class Members wishing to exclude themselves from or object to the Proposed Settlement must do so as outlined in the Notice of Proposed Class Action Settlement, available by visiting the informational website www.SimonetPaxilCRSettlement.com or by calling 1-866-458-3186. Those wishing to exclude themselves from the Proposed Settlement must do so no later than May 15, 2009. Those wishing to object to the Proposed Settlement must do so no later than July 1, 2009. A Class Member must remain in the Class in order to object.

The Court has appointed the law firms Strange & Carpenter and Salas & Co., L.C. to represent the proposed Class. The Court will hold a Final Approval Hearing on July 10, 2009. At that time, the Court will consider the motion for attorneys' fees and expenses, and it will decide whether the Proposed Settlement is fair, reasonable and adequate.

SOURCE Simonet Paxil CR(R) Settlement Administrator.
March 25, 2009 / category: class action / link / comments (0)

Categories:

Leave a comment

Sponsors